|
In der ad hoc stehen wesentlich mehr Informationen (z.B Zeitraum 10 Jahre) 10.03.2004 Ad-hoc-announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Biolitec AG signs exclusive distribution agreement for Foscan(R) in South Korea - Gross sales in Asia expected to grow to Euro 6 million in the medium term. Jena, March 9th, 2004 - Biolitec AG has signed an exclusive agreement with Daewoong Pharm Co Ltd, South Korea, for the distribution of its photodynamic therapeutic drug Foscan(R). Daewoong will exclusively market Foscan(R) in South Korea. The sales agreement with the Daewoong is a further indication of the international appeal of Foscan(R) and marks the continued penetration of Foscan into the Asian market. This follows the signing of a previous sales agreement with a Taiwanese distributor in July last year. Daewoong has annual sales of about US$250 million and is the number two ethical pharmaceuticals company in Korea by sales revenue. This sales agreement serves as a vote of confidence in the efficacy and market potential of Foscan(R). Daewoong will also be an important reference customer for the Asian market. The contract has ten year validity with an auto-renewal clause. With the signing of the contract, Daewoong has also purchased 200 vials of Foscan for use in the first year following marketing regulatory approval. Biolitec estimates gross sales revenue from its Korean and Taiwan distributors to be worth approximately EUR 6 million in the medium term. According to biolitec pharma Ltd. in Scotland, the cost of Foscan(R) treatments for palliative head and neck cancer is about 30 to 40 percent lower than alternatives like chemotherapy or surgery. As a result of cost pressures in the world health care market, biolitec expects an increase in Foscan(R) use for the treatment of palliative head and neck cancer. end of ad-hoc-announcement (c)DGAP 10.03.2004 -------------------------------------------------------------------------------- WKN: 521340; ISIN: DE0005213409; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart |
|
| aus der Diskussion: | biolitec- Jahresabschluss |
| Autor (Datum des Eintrages): | esperanto1979 (10.03.04 12:43:09) |
| Beitrag: | 148 von 241 (ID:12390157) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |